Format

Send to

Choose Destination
Am J Transplant. 2010 Jul;10(7):1517-23. doi: 10.1111/j.1600-6143.2010.03156.x.

Thrombotic microangiopathy after kidney transplantation.

Author information

1
Clinical Research Center for Rare Diseases 'Aldo e Cele Daccò', Mario Negri Institute for Pharmacological Research, Ranica, Bergamo, Italy. marina.noris@marionegri.it

Abstract

Thrombotic microangiopathy (TMA) is a severe complication of kidney transplantation that often causes graft failure. TMA may occur de novo, often triggered by immunosuppressive drugs and acute antibody-mediated rejection, or recur in patients with previous history of hemolytic uremic syndrome (HUS). Recurrent TMA is very rare in patients who had developed end-stage renal failure following HUS caused by Shiga-toxin producing E. scherichia coli, whereas disease recurrence is common in patients with atypical HUS (aHUS). The underlying genetic defect greatly impacts the risk of posttransplant recurrence in aHUS. Indeed recurrence is almost the rule in patients with mutations in genes encoding factor H or factor I, whereas patients with a mutation in membrane-cofactor-protein gene have a good transplant outcome. Prophylactic and therapeutic options for posttransplant TMA, including plasma therapy, combined kidney and liver transplantation and targeted complement inhibitors are discussed in this review.

[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center